
Xeris Biopharma Holdings, Inc. (XERS) Stock Ticker
XERS right now
Market factors today
Unlock the full XERS picture
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS stock facts
| Ticker symbol | XERS |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.6B |
| CEO | John Shannon |
| Employees | 435 |
| Headquarters | Chicago, IL, US |
| IPO date | 2018-06-21 |
| Website | www.xerispharma.com |
What you can see for XERS on Tickr
Live XERS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the XERS report.
Rankings
FAQ
What is the ticker symbol for Xeris Biopharma Holdings, Inc.?
The ticker symbol for Xeris Biopharma Holdings, Inc. is XERS, listed on the NASDAQ Global Select.
What is XERS?
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic,…